



Journal Homepage: - [www.journalijar.com](http://www.journalijar.com)

## INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/16947

DOI URL: <http://dx.doi.org/10.21474/IJAR01/16947>



### RESEARCH ARTICLE

#### VENTILATOR-ASSOCIATED PNEUMONIA IN A TERTIARY CARE INTENSIVE CARE UNIT: RISK FACTORS AND MICROBIAL PROFILE

Anupama S. Wyawahare<sup>1</sup>, Sai Wyawahare<sup>2</sup>, Manjushree Mulay<sup>3</sup>, Vishvesh Bansal<sup>4</sup>, Shraddha Naik<sup>5</sup> and Anita Verulkar<sup>6</sup>

1. Professor, Microbiology Department MGM's Medical College & Hospital Chhatrapati Sambhaji Nagar [Aurangabad] Maharashtra [India].
2. JR III, Microbiology Department Government Medical College Chhatrapati Sambhaji Nagar [Aurangabad].
3. Professor & Head Microbiology Department MGM's Medical College & Hospital Chhatrapati Sambhaji Nagar [Aurangabad].
4. Associate Professor Microbiology Department MGM's Medical College & Hospital Chhatrapati Sambhaji Nagar [Aurangabad].
5. Assistant Professor Microbiology Department MGM's Medical College & Hospital Chhatrapati Sambhaji Nagar [Aurangabad].
6. Assistant Nursing Superintendent MGM's Medical College & Hospital Chhatrapati Sambhaji Nagar [Aurangabad].

#### Manuscript Info

##### Manuscript History

Received: 20 March 2023

Final Accepted: 22 April 2023

Published: May 2023

##### Key words:-

Ventilator associated pneumonia (VAP),  
Risk factors, Antimicrobial resistance

#### Abstract

For creating efficient preventative strategies, knowledge of the etiology, antibiotic resistance patterns and risk factors for developing Ventilator associated pneumonia [VAP] in ICU patients is essential. This prospective observation across-sectional two-year study was done to recognize risk factors for the development of VAP, causative agents and their antimicrobial susceptibility pattern. Fifty late onset VAP and 26 early onset VAP patients were examined. Prolonged mechanical ventilation, reintubation, and tracheostomy were identified as important risk factors. Acinetobacter baumannii complex Klebsiella pneumoniae were the main bacterial pathogens. The idea of differentiating pathogens based on late and early onset VAP may no longer be useful for empirical therapy. Identifying the risk factors can aid in prevention of VAP in ICU patients.

Copy Right, IJAR, 2023.. All rights reserved.

#### Introduction:-

In ICU patients, ventilator-associated pneumonia (VAP) is a typical hospital-acquired infection associated with higher mortality and morbidity

<sup>1,2,3</sup> Depending on the type of hospital intensive care unit, and the population studied, the incidence of VAP differs across studies. <sup>4,5,6</sup> Early-

onset VAP typically has a better prognosis, is less severe, and is more likely to be the result of bacteria that are antibiotic-sensitive. Multidrug-resistant (MDR) microorganisms are the source of late-

onset VAP, which is linked to higher morbidity and mortality rates. <sup>7</sup> There are various risk factors that are closely related to both early-onset and late-

onset VAP. <sup>4</sup> The demographic of patients in an intensive care unit, the local epidemiology, the length of the hospital stay, and an past antibiotic medication all play a significant role in determining the causative agents. <sup>3,5,7,8</sup>

**Corresponding Author:- Anupama S. Wyawahare**

Address:- Professor, Microbiology Department MGM's Medical College & Hospital Chhatrapati Sambhaji Nagar [Aurangabad] Maharashtra [India].

Gram-negative bacteria such as *Acinetobacter* spp., *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* and *Staphylococcus aureus* among Gram-positive cocci are frequent etiologic agents.<sup>3,9,10</sup> Knowledge of antimicrobial susceptibility patterns of pathogens causing VAP is essential for optimal antibiotic therapy.<sup>3,8,10</sup>

With this background our study aims to detect bacterial pathogens of VAP, determine their antibiotic resistance pattern and determine the primary risk factors for the emergence of VAP in admitted ICU patients in MGM medical college and hospital, Aurangabad.

### Material & Methods:-

This prospective observational cross-sectional study was undertaken after approval by Institutional ethical committee. The study was conducted in intensive care units (ICU) of MGM Medical College & Hospital Aurangabad, Maharashtra (India) from January 2019 to December 2020.

All VAP patients having the age of 18 or older was included in the study. Patient intubated in other hospital and developed pneumonia on admission or within 48 hrs of intubation & those suspected VAP cases lacking bacteriological confirmation were excluded.

According to CDC guidelines, ventilator-associated pneumonia (VAP) was identified. [8] The classification was done based on the duration of mechanical ventilation until the date of event [DOE]. Early-onset VAP was defined as VAP that appeared within the first 4 days of hospitalization, and late-onset VAP as VAP that appeared beyond those 4 days. [2, 7, 8]. The analysis only included the first episode; following episodes were not included.

Gram staining, culture and antimicrobial susceptibility test (AST) of endotracheal tube aspirate (ETA) obtained from these patients was carried out. All samples were inoculated on MacConkey's agar and 5% sheep blood agar using a calibrated loop. The plates were incubated overnight at 37°C. Those cases in which gram stain showed <10 squamous epithelial cells and >25 neutrophils and on culture growth of organism with colony count more than 10<sup>5</sup> CFU/ml were included in the study. After initial characterization of the isolates using gram stain, colony morphology and biochemical reactions like catalase, oxidase etc; Vitek ID and AST cards were selected & bacterial suspension was processed for species identification & antimicrobial susceptibility testing as per the manufacturer's instructions (BioMérieux). Antimicrobial agents that are available in Vitek 2 AST panels were included in the study.


Medical records and bedside charts were used to document the clinical data of the patient. Location information, including age, sex, DOE, the date on which mechanical ventilation was started and the method used to enter the patient's airway, such as oral tracheal intubation or tracheostomy, number of ventilator days, reintubation, surgery etc were recorded as per format for data collection. Patients' position was routinely observed. A report of routine investigations like radiological findings before and after mechanical ventilation, culture and sensitivity of endotracheal secretions & tracheal secretions was also noted. In present study, 76 ventilator-associated pneumonia patients in total were examined.

Patients on ventilator were regularly monitored for ventilator-associated pneumonia. Incidence of VAP case was generated by clinicians/residents from various ICUs. Also, patients on ventilator were regularly monitored for ventilator-associated pneumonia by infection control nursing staff. Relevant patient data including the no. of ventilator days and various risk factors was collected by infection control nursing staff. Data was verified by the infection prevention and control team to confirm VAP case. All relevant clinical and laboratory data was analysed.

### Result:-


Out of the 76 cases, 50 (65.78%) were classified as having a late onset and 26 (34.21%) as having a nearly onset VAP. Males 53 (69.73%) had a higher frequency of VAP than did females 23 (30.26%) and in various age groups, patients had the highest prevalence of VAP in age group of 51-60 years 19 (25%). Maximum patients of VAP were from MICU followed by MCRI ICU and SICU.

ChartNo1:- AnalysisofVAPcases.



AnalysisofVAPcasesisshowninchartNo1.Outof76patients17requiredreintubation.Inourstudyaveragedaysofmechanicalventilationwas18.39days.Outof76patientsofVAPendotrachealintubationwasrequiredin73patients[96.05%]andtracheostomyin36patients[47.36%];19[25%]patientswereimmunocompromised,fivepatients[6.57%]weresufferingfromchroniclungdisease.Depressedlevelofconsciousnesswaspresentin67cases[88.15%],sixpatientsgavehistoryof[Head,neckorthoracic]surgery.

Outof76cases26[34.21%]hadearlyonsetVAPand50[65.78%]developedlateonsetVAP.InbothlateandearlyonsetVAPpredominantpathogenswereAcinetobacterbaumannicomplexfollowedbyKlebsiellapneumoniae.Total83organismswereisolatedfromVAPcases;outofwhichpredominantisolatewasAcinetobacterbaumannicomplex35(42.16%)followedby25(30.12%)Klebsiellapneumoniaeand8(9.6%)Pseudomonasaeruginosa.[SeeChartNo2]

**ChartNo2:-** DistributionofOrganismsisolatedfromearlyandlate-onsetVAPcases.

All isolates of *Acinetobacter baumannii* complex from VAP cases were resistant to Cefepime, Ceftazidime, Ciprofloxacin, Doxycycline, Imipenem, Meropenem & Piperacillin/Tazobactam.

Better susceptibility was found only against Colistin [100%] followed by Minocycline [63.64%] Trimethoprim+Sulfamethoxazole [35.3%], Cefoperazone+Sulbactam [24.75%] & Levofloxacin [8%] & Gentamicin [3.04%].

Out of *Klebsiella pneumoniae* isolates [96%] were resistant to Ciprofloxacin followed by Cefuroxime [95.45%], Ceftriaxone [95.45%], Meropenem [93.33%], Cefepime [92%] Amoxicillin+Clavulanic acid [88%], Ertapenem [86.36%] Cefoperazone+Sulbactam [80%] Imipenem [81.81%] & Trimethoprim+Sulfamethoxazole [80%].

*Klebsiella pneumoniae* isolates were susceptible to Colistin [90.09%] followed by Piperacillin/Tazobactam [57.14%], Gentamicin [40%], Amikacin [40%] and Tigecycline [36.36%].

### Discussion:-

In ICU patients, a frequent hospital-acquired illness known as ventilator-associated pneumonia (VAP) is linked to increased mortality and morbidity.<sup>1,2,3</sup>

The VAP bundle included 30<sup>0</sup>-45<sup>0</sup> head elevation, sedation break each day, evaluation of extubation readiness, prophylaxis for deep vein thrombosis, peptic ulcer disease, suction from endotracheal tube to keep ventilator circuits dry and twice daily use of 2% chlorhexidine twice a day as per requirement and hand hygiene guidelines are implemented in our hospital to prevent VAP infection.

A total of 76 adult VAP patients in total were assessed. VAP rate was observed to be more prevalent among males 53 (69.73%) and mean age group was 51-60 yrs.

In a study carried out by Uzza et al 52% of the patients were VAP with early onset, while 48% were VAP with late onset.<sup>7</sup> In our study out of 76 cases 50 (65.78%) acquired late-onset VAP, while 26 (34.21%) had early-onset VAP which may be due to differences in study period & population studied.

Endotracheal intubation is a significant risk factor that can lead to secretion sticking around the cuff, the development of a bacterial biofilm, microaspiration during the intubation process and impaired mucociliary clearance of secretions. Replacement of normal flora by pathogens and the ventilator's positive pressure helps forward movement of bacterium-enriched material.<sup>8</sup> In present study endotracheal intubation required in 73 patients [96.05%]. Risk is higher in patients of tracheostomy as manipulation of the airway may predispose to aspiration followed by VAP. In our study 36 (47.36%) patients require tracheostomy.

Reintubation is one of the risk factors for the emergence of VAP. Aspiration risk may be increased as a result of slowed reflexes brought on by prolonged intubation or altered level of consciousness.<sup>1,4</sup> In our study 17 patients required reintubation.

Patients with consciousness issues had considerably longer hospital stays and longer periods on mechanical ventilation, which exposed them to more microorganisms and increased their risk of developing VAP.<sup>11</sup> In present study depressed level of consciousness was present in 67 [88.15%] patients.

Out of 76 patients 19 [25%] were immunocompromised, 5 (6.57%) patients were suffering from chronic lung disease, 06 [7.89%] gave history of head, neck or thoracic surgery.

Predominant pathogens in both late and early onset VAP were *Acinetobacter baumannii* complex followed by *Klebsiella pneumoniae*.

The duration of mechanical ventilation typically affects the VAP causing agent. Early VAP is typically caused by infections that respond well to antibiotics, but late onset VAP is caused by organisms that are multi-drug resistant.

<sup>8</sup> However, in our study both late-onset and early-onset VAP were associated with MDR infection this may be because of prolonged hospitalization and prior antibiotic therapy. Our findings are in concordance with study by Ben Lakhal et al in which there are no discernible distinctions between MDR pathogens linked to early-onset or late-onset VAP in their patterns of resistance.

<sup>12</sup> Ben Lakhal et al reported *A. baumannii* (53%), *P. aeruginosa* (37%) and *Enterobacteriales* (28%), which included *K. pneumoniae*, *Enterobacter cloacae* complex, *E. coli*, *Proteus mirabilis*, *Providencia stuartii* and *Serratia marcescens* were the most frequently isolated organisms from VAP cases.<sup>12</sup> In a study at Bangalore; *Pseudomonas aeruginosa*, *E. coli* and *Acinetobacter baumannii* were found in both early onset and late onset VAP isolates.<sup>13</sup>

In our study *Acinetobacter baumannii* complex was the most common pathogen found in patients with late-onset and early-onset VAP followed by *Klebsiella pneumoniae*.

All isolates of *Acinetobacter baumannii* complex from VAP cases were resistant to cefepime, ceftazidime, ciprofloxacin, doripenem, imipenem, meropenem & piperacillin / tazobactam. All isolates of *Acinetobacter baumannii* complex were susceptible to colistin [100%].

Out of *Klebsiella pneumoniae* isolates [96%] were resistant to ciprofloxacin followed by cefuroxime [95.45%], ceftriaxone [95.45%], meropenem [93.33%], cefepime [92%], amoxicillin + clavulanic acid [88%], ertapenem [86.36%], cefoperazone + sulbactam [80%], imipenem [81.81%] & trimethoprim + sulfamethoxazole [80%]. Better susceptibility was found only against colistin [90.09%] followed by piperacillin / tazobactam [57.14%].

Many clinicians treat critically ill patients empirically with a mix of broad-spectrum antibiotics due to rising antimicrobial resistance rates, which can exacerbate the development of resistance.<sup>14</sup> Rational use of appropriate antibiotics and unnecessary prolonged hospitalization may reduce patient colonization and subsequent development of VAP with MDR pathogens.

**Treatment for VAP brought on by multidrug-resistant *A. baumannii* can be accomplished with intravenously administered colistin.**<sup>15</sup> Only after all other tested antibiotics have failed colistin and polymixin B can be given.<sup>16</sup>

According to our findings, a list should be kept as a reserve drug to treat these MDR infections. Programs for awareness among staff and clinicians to reduce unnecessary antibiotic prescription, proper training of staff on infection prevention & control practices, prudent use of antibiotics is crucial in preventing MDR infections in VAP patients.

### Conclusion:-

In present study both early and late onset VAP occurred in 34.21% and 65.78% of patients, respectively. Prolonged mechanical ventilation, reintubation, tracheostomy and depressed level of consciousness were important risk factors. Patients with both late and early onset VAP were infected with multi drug resistant bacteria. *Acinetobacter baumannii* complex followed by *Klebsiella pneumoniae*. When selecting the best empirical antibiotic therapy, the idea of differentiating pathogens based on early and late VAP may no longer be applicable. We strongly recommend to follow easy infection prevention methods like hand hygiene, transmission based precautions, programs for awareness among staff to lower the rate of needless antibiotic prescription, decrease reintubation rates by proper training of staff and follow aseptic techniques that will prevent spread of infection. Also, Antibiotic usage should be done carefully to avoid MDR infections brought on by VAP.

### Acknowledgements:-

The author thanks the Dean of our college, other healthcare professionals of our hospital without their cooperation and generous assistance this study would not have been possible.

### Conflict of interest

None declared.

### References:-

- 1] Gadani, Hina, Vyas, Arun & Kar, Akhya. A study of ventilator-associated pneumonia: Incidence, outcome, risk factors and measures to be taken for prevention. *Indian journal of anaesthesia*. 2010;54(6):535-540
- 2] Ranjan N, Chaudhary U, Chaudhry D, Ranjan KP. Ventilator-associated pneumonia in a tertiary care intensive care unit: Analysis of incidence, risk factors and mortality. *Indian J Crit Care Med*. 2014 Apr;18(4):200-4.
- 3] Chaudhury A, Rani AS, Kalawat U, Sumant S, Verma A, Venkataramana B. Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India. *Indian J Med Res*. 2016 Sep;144(3):440-446.
- 4] Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC. Ventilator-associated pneumonia in a tertiary care hospital in India: incidence and risk factors. *J Infect Dev Ctries*. 2009 Dec 15;3(10):771-7.
- 5] Gupta A, Agrawal A, Mehrotra S, Singh A, Malik S, Khanna A. Incidence, risk stratification, antibiogram of pathogen isolated and clinical outcome of ventilator-associated pneumonia. *Indian J Crit Care Med*. 2011 Apr;15(2):96-101
- 6] Deepak Jose, Sheela Kurian V. Incidence and Risk Factors for Ventilator Associated Pneumonia in ICU of Medical College Hospital Kottayam. *JMSCR*. 2017, September, Vol 05(09):27788-27791.
- 7] Mallick UK, Faruq MO, Ahsan AA, Fatema K, Ahmed F, Asaduzzaman M, Islam M, Sultana A. Spectrum of early onset and late onset ventilator-associated pneumonia (vap) in a tertiary care hospital of Bangladesh: A prospective cohort study. *Bangladesh Critical Care Journal*. 2015 Jul 10;3(1):9-13.
- 8] Kalanuria AA, Ziai W, Mirski M. Ventilator-associated pneumonia in the ICU. *Crit Care*. 2014 Mar 18;18(2):208.
- 9] Mehta Y, Jaggi N, Rosenthal VD, Rodrigues C, Todi SK, Saini N, Udhwadia FE, Karlekar A, Kothari V, Myatra SN, Chakravathy M, Singh S, Dwivedy A, Sen N, Sahu S. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in 21 adult intensive care units from 10 cities in India: findings of the International Nosocomial Infection Control Consortium (INICC). *Epidemiol Infect*. 2013 Dec;141(12):2483-91.
- 10] Patro S, Sarangi G, Das P, Mahapatra A, Mohapatra D, Paty BP, Chayani N. Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospital. *Indian J Pathol Microbiol*. 2018 Jul-Sep;61(3):375-379.
- 11] Wu D, Wu C, Zhang S, Zhong Y. Risk factors of ventilator-associated pneumonia in critically ill patients. *Frontiers in pharmacology*. 2019 May 9(10):482.
- 12] Ben Lakhal H, M'Rad A, Naas T, Brahmi N. Antimicrobial Susceptibility among Pathogens Isolated in Early- versus Late-Onset Ventilator-Associated Pneumonia. *Infect Dis Rep*. 2021 Apr 27;13(2):401-410.
- 13] Golia S, KTS, CLV. Microbial profile of early and late onset ventilator-associated pneumonia in the intensive care unit of a tertiary care hospital in Bangalore, India. *J Clin Diagn Res*. 2013 Nov;7(11):2462-6.
- 14] Guillamet CV, Kollef MH. Update on ventilator-associated pneumonia. *Curr Opin Crit Care*. 2015 Oct;21(5):430-8.

- 15]Garnacho-MonteroJ,Ortiz-LeybaC,Jiménez-JiménezFJ,Barrero-AlmodóvarAE,García-GarmendiaJL,Bernabeu-WittelIM,Gallego-LaraSL,Madrado-OsunaJ.Treatmentofmultidrug-resistantAcinetobacterbaumanniiventilator-associatedpneumonia(VAP)withintravenouscolistin:acomparisonwithimipenem-susceptibleVAP.ClinInfectDis.2003May1;36(9):1111-8.
- 16]TreatmentGuidelinesforAntimicrobialUseinCommonSyndromes,ICMR,NewDelhi,India;2019:113.